These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 26096679)

  • 21. Insights into the structure and pharmacology of the human trace amine-associated receptor 1 (hTAAR1): homology modelling and docking studies.
    Cichero E; Espinoza S; Gainetdinov RR; Brasili L; Fossa P
    Chem Biol Drug Des; 2013 Apr; 81(4):509-16. PubMed ID: 22883051
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Discovery of a potent and selective free fatty acid receptor 1 agonist with low lipophilicity and high oral bioavailability.
    Christiansen E; Due-Hansen ME; Urban C; Grundmann M; Schmidt J; Hansen SV; Hudson BD; Zaibi M; Markussen SB; Hagesaether E; Milligan G; Cawthorne MA; Kostenis E; Kassack MU; Ulven T
    J Med Chem; 2013 Feb; 56(3):982-92. PubMed ID: 23294321
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Identification of highly potent and orally available free fatty acid receptor 1 agonists bearing isoxazole scaffold.
    Li Z; Liu C; Shi W; Cai X; Dai Y; Liao C; Huang W; Qian H
    Bioorg Med Chem; 2018 Feb; 26(3):703-711. PubMed ID: 29291938
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Novel GPR119 agonist HD0471042 attenuated type 2 diabetes mellitus.
    Ha TY; Kim YS; Kim CH; Choi HS; Yang J; Park SH; Kim DH; Rhee JK
    Arch Pharm Res; 2014 May; 37(5):671-8. PubMed ID: 23897163
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Novel agonists of free fatty acid receptor 1 (GPR40) based on 3-(1,3,4-thiadiazol-2-yl)propanoic acid scaffold.
    Krasavin M; Lukin A; Zhurilo N; Kovalenko A; Zahanich I; Zozulya S
    J Enzyme Inhib Med Chem; 2016 Dec; 31(6):1404-10. PubMed ID: 26899762
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Discovery of a biaryl cyclohexene carboxylic acid (MK-6892): a potent and selective high affinity niacin receptor full agonist with reduced flushing profiles in animals as a preclinical candidate.
    Shen HC; Ding FX; Raghavan S; Deng Q; Luell S; Forrest MJ; Carballo-Jane E; Wilsie LC; Krsmanovic ML; Taggart AK; Wu KK; Wu TJ; Cheng K; Ren N; Cai TQ; Chen Q; Wang J; Wolff MS; Tong X; Holt TG; Waters MG; Hammond ML; Tata JR; Colletti SL
    J Med Chem; 2010 Mar; 53(6):2666-70. PubMed ID: 20184326
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Discovery of benzofuran propanoic acid GPR120 agonists: From uHTS hit to mechanism-based pharmacodynamic effects.
    Lombardo M; Bender K; London C; Plotkin MA; Kirkland M; Mane J; Pachanski M; Geissler W; Cummings J; Habulihaz B; Akiyama TE; Di Salvo J; Madeira M; Pols J; Powles MA; Finley MF; Johnson E; Roussel T; Uebele VN; Crespo A; Leung D; Alleyne C; Trusca D; Lei Y; Howard AD; Ujjainwalla F; Tata JR; Sinz CJ
    Bioorg Med Chem Lett; 2016 Dec; 26(23):5724-5728. PubMed ID: 27815121
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Continued SAR exploration of 1,2,4-thiadiazole-containing scaffolds in the design of free fatty acid receptor 1 (GPR40) agonists.
    Krasavin M; Lukin A; Bakholdina A; Zhurilo N; Onopchenko O; Borysko P; Zozulya S; Moore D; Tikhonova IG
    Eur J Med Chem; 2017 Nov; 140():229-238. PubMed ID: 28938138
    [TBL] [Abstract][Full Text] [Related]  

  • 29. TAK-875, an orally available G protein-coupled receptor 40/free fatty acid receptor 1 agonist, enhances glucose-dependent insulin secretion and improves both postprandial and fasting hyperglycemia in type 2 diabetic rats.
    Tsujihata Y; Ito R; Suzuki M; Harada A; Negoro N; Yasuma T; Momose Y; Takeuchi K
    J Pharmacol Exp Ther; 2011 Oct; 339(1):228-37. PubMed ID: 21752941
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CoMSIA study on substituted aryl alkanoic acid analogs as GPR40 agonists.
    Bhatt A; Patel PD; Patel MR; Singh S; Lau-Cam CA; Talele TT
    Chem Biol Drug Des; 2011 May; 77(5):361-72. PubMed ID: 21352503
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Structure-activity relationships of GPR120 agonists based on a docking simulation.
    Sun Q; Hirasawa A; Hara T; Kimura I; Adachi T; Awaji T; Ishiguro M; Suzuki T; Miyata N; Tsujimoto G
    Mol Pharmacol; 2010 Nov; 78(5):804-10. PubMed ID: 20685848
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Design, synthesis, and biological activity of potent and orally available G protein-coupled receptor 40 agonists.
    Sasaki S; Kitamura S; Negoro N; Suzuki M; Tsujihata Y; Suzuki N; Santou T; Kanzaki N; Harada M; Tanaka Y; Kobayashi M; Tada N; Funami M; Tanaka T; Yamamoto Y; Fukatsu K; Yasuma T; Momose Y
    J Med Chem; 2011 Mar; 54(5):1365-78. PubMed ID: 21319751
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Synthesis and activity of small molecule GPR40 agonists.
    Garrido DM; Corbett DF; Dwornik KA; Goetz AS; Littleton TR; McKeown SC; Mills WY; Smalley TL; Briscoe CP; Peat AJ
    Bioorg Med Chem Lett; 2006 Apr; 16(7):1840-5. PubMed ID: 16439116
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Free fatty acid receptor 1 (FFA1/GPR40) agonists: mesylpropoxy appendage lowers lipophilicity and improves ADME properties.
    Christiansen E; Due-Hansen ME; Urban C; Grundmann M; Schröder R; Hudson BD; Milligan G; Cawthorne MA; Kostenis E; Kassack MU; Ulven T
    J Med Chem; 2012 Jul; 55(14):6624-8. PubMed ID: 22724451
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Identification of potential dual agonists of FXR and TGR5 using e-pharmacophore based virtual screening.
    Sindhu T; Srinivasan P
    Mol Biosyst; 2015 May; 11(5):1305-18. PubMed ID: 25787676
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Discovery and optimization of 5-(2-((1-(phenylsulfonyl)-1,2,3,4-tetrahydroquinolin-7-yl)oxy)pyridin-4-yl)-1,2,4-oxadiazoles as novel gpr119 agonists.
    Wang Y; Yu M; Zhu J; Zhang JK; Kayser F; Medina JC; Siegler K; Conn M; Shan B; Grillo MP; Liu JJ; Coward P
    Bioorg Med Chem Lett; 2014 Feb; 24(4):1133-7. PubMed ID: 24440299
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Identification of residues important for agonist recognition and activation in GPR40.
    Sum CS; Tikhonova IG; Neumann S; Engel S; Raaka BM; Costanzi S; Gershengorn MC
    J Biol Chem; 2007 Oct; 282(40):29248-55. PubMed ID: 17699519
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Synthesis and structure-activity relationship of non-phosphorus-based fructose-1,6-bisphosphatase inhibitors: 2,5-Diphenyl-1,3,4-oxadiazoles.
    Liao BR; He HB; Yang LL; Gao LX; Chang L; Tang J; Li JY; Li J; Yang F
    Eur J Med Chem; 2014 Aug; 83():15-25. PubMed ID: 24946215
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Discovery and optimization of a novel series of N-arylamide oxadiazoles as potent, highly selective and orally bioavailable cannabinoid receptor 2 (CB2) agonists.
    Cheng Y; Albrecht BK; Brown J; Buchanan JL; Buckner WH; DiMauro EF; Emkey R; Fremeau RT; Harmange JC; Hoffman BJ; Huang L; Huang M; Lee JH; Lin FF; Martin MW; Nguyen HQ; Patel VF; Tomlinson SA; White RD; Xia X; Hitchcock SA
    J Med Chem; 2008 Aug; 51(16):5019-34. PubMed ID: 18680277
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Structural modifications of N-arylamide oxadiazoles: Identification of N-arylpiperidine oxadiazoles as potent and selective agonists of CB2.
    DiMauro EF; Buchanan JL; Cheng A; Emkey R; Hitchcock SA; Huang L; Huang MY; Janosky B; Lee JH; Li X; Martin MW; Tomlinson SA; White RD; Zheng XM; Patel VF; Fremeau RT
    Bioorg Med Chem Lett; 2008 Aug; 18(15):4267-74. PubMed ID: 18640038
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.